The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support Amvuttra’s Phase 3 HELIOS-B trial The transaction excludes ...
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results